AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03203967 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Single femoral nerve block
Description: Single femoral nerve block is performed with 20 ml 0.5% ropivacaine under the guidance of ultrasonography and nerve stimulator after surgery.
Study NCT03203967 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intravenous morphine analgesia
Description: Intravenous morphine analgesia is provided with a patient-controlled analgesia pump which is established with 100 ml of 0.5 mg/ml morphine, programmed to deliver a 2 ml bolus with a lockout interval of 8-10 min and a background infusion of 0.5 ml/h.
Study NCT03203967 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Intravenous morphine analgesia
Description: Intravenous morphine analgesia is provided with a patient-controlled analgesia pump which is established with 100 ml of 0.5 mg/ml morphine, programmed to deliver a 2 ml bolus with a lockout interval of 8-10 min and a background infusion of 0.5 ml/h.
Study NCT00494702 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Resuscitation
Description: Use of inspiratory fraction of oxygen needed to achieve oxygen saturation in the preset limits 85-88%
Study NCT00494702 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Resuscitation
Description: Oxygen inspiratory fraction needed to keep oxygen saturation in the preset limits of 90-93%
Study NCT03732963 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (Group P)
Description: Group P: 20 patients will receive a placebo tablet preoperatively.
Study NCT03732963 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Melatonin (Group M)
Description: Group M: 20 patients will receive an oral melatonin tablet 10 mg preoperatively.
Study NCT04362670 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OTX-CSI
Description: OTX-CSI intracanalicular insert
Study NCT04362670 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Vehicle
Description: Hydrogel Vehicle intracanalicular insert
Study NCT05016739 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CADISS
Description: The CADISS® device was procured from AuXin Surgery. It consists in three elements:~1. A single use disposable Remote Kit, containing a sterile cartridge, which prepares the Drug Product immediately before use, and the sterile tubing for fluid connexion. The Drug Product is a 30 ml sterile 5% mesna solution of pH 7.3+/-0.5~2. Reusable stainless steel non-cutting mechanical instruments similar to those used in the normal practice, except for the provision of an internal irrigation channel bringing the Drug Product at the working edge.~3. A pedal controlled electric motor driving the peristaltic cassette included in the disposable tubing in order to control the dispensing of the Drug Product during the procedure.
Study NCT01330303 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Reference formulation
Description: SECOTEX® (tamsulosin hydrochloride) 0,4 mg (Boehringer Ingelheim)
Study NCT01330303 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Test formulation
Description: tamsulosin hydrochloride 0,4 mg (Synthon BV)
Study NCT03564158 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: meropenem-vaborbactam
Description: Meropenem-Vaborbactam being studied for effects on TQT
Study NCT03564158 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT03799965 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: ERAS (Enhanced Recovery After Surgery ) are evaluated
Description: In this arm ERAS( Enhanced Recovery After Surgery) protocol will be inserted.The findings regarding the patients under ERAS protocol are evaluated based on evidence.
Study NCT03799965 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: ERAS are not evaluated
Description: In this arm ERAS( Enhanced Recovery After Surgery) protocol will not be inserted.The findings regarding the patients under ERAS protocol are evaluated based on evidence.
Study NCT02152761 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Matching placebo was administered as intravenous infusion starting on Day 1 until week 20.
Study NCT01255618 — intervention group
Intervention type: DEVICE
Intervention: INVOS 5100
Description: Near-infrared range and has been used in newborn infants since 1985. Fibre-optic bundles or optodes are placed either on opposite sides of the tissue being interrogated (usually a limb or the head of a young baby) to measure transmitted light, or close together to measure reflected light. Light enters through one optode and a fraction of the photons is captured by a second optode and conveyed to the measuring device. NIRS uses a frequency band between 650 nm and 1000 nm and relies on three important phenomena: (1) human tissue is relatively transparent to light in the near-infrared region of the spectrum; (2) pigmented compounds known as chromophores absorb light as it passes through biological tissue; and (3) human tissues contain substances whose absorption spectra at near-infrared wavelengths are well defined and depend on their oxygenation status.
Study NCT00002723 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: suramin
Description: 3.192g/square meter total dose given decreasing concentrations in 250 cc normal saline IV over 1 hour on days 1,2,8,9,29,30,36,37,57,58,64,and 65.
Study NCT00002723 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: suramin
Description: 5.320 g/square meter total dose given in decreasing concentrations in 250 cc normal saline via IV over 1 hour on days 1,2,8,9,29,30,36,37,57,58,64,and 65
Study NCT03564158 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Moxifloxacin
Description: Active Comparator
Study NCT04629378 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Meropenem Injection
Description: Meropenem IV 6 grams
Study NCT04629378 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amoxicillin Clavulanate
Description: Amx/CA oral 1000/62.5mg 2 tablets
Study NCT04629378 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pyrazinamide
Description: Pyrazinamide 20-30mg/kg
Study NCT04629378 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bedaquiline
Description: Bedaquiline 400mg
Study NCT04629378 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rifafour
Description: Rifafour (HRZE) Standard dose
Study NCT02535403 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ICBT
Study NCT00149461 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Written Asthma Action Plan
Study NCT02689583 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Antibiotic selection based on the antibiotic susceptibility testing
Description: The biological intervention focused on the results from the antibiotic susceptibility testing. All patients should used the their susceptibility antibiotics according to antibiotic susceptibility testing of H. pylori. Considering the safety of drug usage, priority antibiotic selection was as follow: Amoxicillin > Clarithromycin > Levofloxacin >Tetracycline > Furazolidone > Metronidazole.
Study NCT02689583 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: PPI selection based on the CYP2C19 gene polymorphism
Description: PPI selection should based on the CYP2C19 gene polymorphism of patients. Patients have different metabolizers, such as poor metabolizers (PM), extensive metabolizers (EM) and intermediate metabolizer (IM). Different metabolism of patients should select different PPI or different doses of PPI. For IM and PM, in this study, patients selected the standard dose of Omeprazole. For EM, in this study, patients selected the Esomeprazole with increasing doses 50%-100%.
Study NCT01494077 — intervention group
Intervention type: OTHER
Intervention: Laboratory processing for results
Description: There is no intervention. Extra fluid that is normally discarded will be processed.
Study NCT00313105 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Smokeless tobacco (Oliver Twist pellets)
Description: individual visits with counseling
Study NCT00313105 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: smoking cessation counseling
Description: individual visits
Study NCT00313105 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: smoking cessation counseling
Description: individual visits
Study NCT02845752 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Respimat
Description: Oral inhalation spray
Study NCT02845752 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo Respimat
Description: Oral inhalation spray
Study NCT02852031 — intervention group
Intervention type: OTHER
Intervention: Collaborative Learning Network
Study NCT04183556 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Naproxen
Description: use of naproxen twice a day orally in mens time
Study NCT04183556 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Naproxen
Description: use of naproxen twice a day orally in mens time
Study NCT04183556 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Turmeric
Description: Use of turmeric orally (1 gram powder formula) in mens time
Study NCT03266328 — intervention group
Intervention type: PROCEDURE
Intervention: Primary Percutaneous Coronary Intervention (PPCI)
Description: Percutaneous Coronary Intervention in patients of acute myocardial infarction diagnosed using ECG findings
Study NCT03934528 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Virtual environment activity
Description: Patients undertake an activity using simulated arm movement within a virtual reality environment every day for two months
Study NCT02689583 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Probiotics usage based on the 16SrRNA sequencing
Description: Different micro-environment in stomach may influence the antibiotic absorption. In this study, some patients could select probiotic as adjuvant therapy according to their micro-environment in stomach by 16SrRNA sequencing.
Study NCT00002723 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Suramin
Description: 7.661 g/square meter toal dose given in decreasing concentrations in 250 cc normal saline IV over 1 hour on days 1,2,8,9,29,30,36,37,5,58,64,and 65.
Study NCT02882321 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxidative Phosphorylation Inhibitor IACS-010759
Description: Given PO
Study NCT02882321 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacological Study
Description: Correlative studies
Study NCT00313105 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: smoking cessation counseling
Description: individual visits
Study NCT01454986 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ALXN1007
Description: Single dose, IV
Study NCT02454933 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD9291
Description: Once daily tablet 80 mg
Study NCT02454933 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MEDI4736
Description: 10mg/kg q2w (IV) infusion
Study NCT00725491 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ganirelix
Description: On day 6 of recFSH treatment, Org 37462 treatment will start by daily SC administration (0.25 mg) up to and including the day of hCG administration.
Study NCT01454986 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Single dose, IV
Study NCT00725491 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: triptorelin
Description: a daily dose of 0.05 mg SC is to be injected. Triptorelin treatment will start in the luteal phase at day 21-24 of the menstrual cycle. Treatment with recFSH will start 14 days later if treatment with triptorelin has resulted in downregulation, i.e. serum E2 \<= 50 pg/ml (\<= 200pmol/l). In case the hypogonadotropic state is not reached after 14 days of pretreatment, the dose of triptorelin will be increased to 0.1 mg. If downregulation is not reached within 28 days of pre-treatment with triptorelin, the subject will be discontinued from further hormonal treatment. The daily dose of triptorelin is sustained up to and including the day of hCG.
Study NCT00133965 — intervention group
Intervention type: BEHAVIORAL
Intervention: Dignity Psychotherapy
Description: At the beginning and at the end of the study, you will be asked to fill out a series of questionnaires.will also receive three visits by a mental health professional over a period of five to seven days. You will be asked to fill out some brief questionnaires during this session which ask about feelings about your illness, symptoms, emotional reactions, and support you have available. The second meeting will be scheduled as soon as you are able to do so, within no more than 24 to 48 hours from your initial session with the Research Staff.The third meeting you will also be asked to fill out several questionnaires,including a specific questionnaire regarding your thoughts about the Dignity Psychotherapy Intervention. Total time commitment for this study should be approximately 120-150 minutes.
Study NCT00133965 — intervention group
Intervention type: BEHAVIORAL
Intervention: Supportive Psychotherapy
Description: you will receive the standard care you normally would receive, but will also receive three visits by a mental health professional over a period of five to seven days. The initial visit will take approximately 45 minutes. You will be asked to fill out brief questionnaires (described above) during this session.A second contact will be scheduled as soon as you are able to do so, within no more than 24 to 48 hours from your initial session with the research staff. During this second session, you will have the opportunity to discuss with a supportive research therapist issues or topics relevant to your experience of coping with cancer.The third and final contact,you will be asked you to fill out questionnaires similar to those you filled out at the beginning of the study. Total time commitment for this study should be approximately 120-150 minutes.
Study NCT01090739 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TOPAS Treatment for Fecal Incontinence
Description: The TOPAS Treatment for Fecal Incontinence is implanted using a minimally invasive trans-obturator approach; two needle passers deliver the sling assembly. Two small posterior incisions facilitate the post-anal placement of the mesh.
Study NCT02964234 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Empowerment
Description: Three group sessions (breast cancer education; communication; volunteerism) 1.5 hours 3 times across 3 weeks
Study NCT02964234 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Education
Description: Three group sessions (breast cancer education; diet; physical activity) 1.5 hours 3 times across 3 weeks
Study NCT02511106 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD9291 80 mg/40 mg
Description: The initial dose of AZD9291 80 mg once daily can be reduced to 40 mg once daily.
Study NCT02511106 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo AZD9291 80 mg/40 mg
Description: The initial dose of Placebo AZD9291 80 mg once daily can be reduced to 40 mg once daily.
Study NCT02511106 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Open-label AZD9291 80 mg/40 mg
Description: Eligible patients will be offered open-label osimertinib upon recurrence and in the absence of intervening systemic anti-cancer therapy.
Study NCT03445624 — intervention group
Intervention type: DRUG
Intervention: Infliximab
Description: follow up the patients who received this drugs for 1 year by abdominal ultrasound,peripheral hemogram and colonoscopy
Study NCT02886052 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Therapist guided Internet-CBT for insomnia
Study NCT02886052 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Active control
Study NCT02049242 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: triple tourniquet
Description: Triple tourniquet consist of two tourniquet applied both infundibulopelvic ligaments and one uterine isthmus to occlude the left and right ovarian vessels and to occlude the uterine arteries. For this purpose, a small opening is made in the avascular place of the broad ligament on either side of the uterine isthmus superior to the uterine vessels. A pediatric Foley catheter is threaded through the two holes and tied tightly anteriorly around the cervix at the level of the internal os.~Through the same openings in the broad ligament each side a Foley catheter looped around the infundibulopelvic ligament lateral to the fallopian tube and ovary.
Study NCT02049242 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Single tourniquet
Description: Single tourniquet is tourniquet applied uterine isthmus to occlude the uterine arteries. For this purpose, a small opening is made in the avascular place of the broad ligament on either side of the uterine isthmus superior to the uterine vessels. A pediatric Foley catheter is threaded through the two holes and tied tightly anteriorly around the cervix at the level of the internal os.
Study NCT00297323 — intervention group
Intervention type: DRUG
Intervention: Topiramate
Description: 75 patients over the age of 2 years old with epilepsy.
Study NCT00345865 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carmustine
Description: Day -6, 300 mg/m\^2 over 2 hour
Study NCT00345865 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide
Description: NHL with radiation: Cyclophosphamide 60 mg/kg intravenous (IV) over two hours daily x 2 days.~HL without radiation: Cyclophosphamide, Days - 6 through -3, 1.5 gm/m\^2 over 2 hours daily x 4 days.~Cyclophosphamide will be dosed based on actual body weight (ABW) unless the patient is 20% or more of ideal body weight (IBW). If more than 20% of ideal body weight, an adjusted ideal body weight (AIBW) will be used for dosing.
Study NCT00345865 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: etoposide
Description: NHL without radiation and cyclophosphamide: Etoposide 100 mg/m2 IV over 2 hours twice daily on Day -5 through -2.~HL without radiation: 150 mg/m\^2 intravenously over 4 hours every 12 hours for 6 total doses on Days -6 through -4.
Study NCT00345865 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: peripheral blood stem cell transplantation
Description: Day 0 infuse PBSC. All patients will have PBSC collected by leukapheresis. Mobilization will be done with G-CSF alone (filgrastim) or using ifosfamide/carboplatin/etoposide and with or without rituximab. Leukapheresis is to begin on Day 5.
Study NCT01565330 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: florbetapir F 18
Description: single dose IV injection
Study NCT03844126 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Transition classes
Description: 90 minutes spent with patients and their families (separately) to review the changes and challenges associated with healthcare transition and help alleviate some of the barriers traditionally associated with this process.
Study NCT02393963 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tranexamic Acid
Description: 0.5g Tranexamic Acid in 0.9% Sodium Chloride (study group) will be injected into the joint after final closure through a temporary catheter that is brought out through the incision.
Study NCT02393963 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 0.9% Sodium Chloride (placebo group) will be injected into the joint after final closure through a temporary catheter that is brought out through the incision.
Study NCT01968018 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tramadol HCI/acetaminophen
Description: Participants will receive tablet of tramadol HCI (37.5 mg)/acetaminophen (325 mg) on Day 1. Participants may increase their daily dosage of study medication is 1 to 2 tablets every 4 to 6 hours as needed for pain relief up to maximum of 8 tablets per day.
Study NCT04729166 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Structured education and follow-up
Description: This structured educational material was developed by the authors on the basis of the literature. Interventions of the study were carried out in the 32nd-42nd week of pregnancy, 3rd-7th day postpartum, and at the 1st month. At first stage, a 15-20-minute education was given to the pregnant women in the study group in the breastfeeding room of the facility, educational booklets were distributed. The main emphasis parts of the education were repeated with a standard summary information form at each follow-up.
Study NCT00091299 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: warfarin
Study NCT04495114 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 40g carbohydrate load (Apple juice)
Description: A 40g carbohydrate drink will be administered to subjects with non-insulin dependent type 2 diabetes 3 hours prior to their operation. This is standard practice in subjects without diabetes.
Study NCT04103333 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Lumbar Puncture
Description: Administered as specified in the treatment arm.
Study NCT04700696 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Peer Recovery Support
Description: Weekly visits with peer who has lived experience related to child welfare and addiction
Study NCT04700696 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Peer Recovery Support
Description: Weekly visits with peer who has lived experience related to child welfare and addiction
Study NCT04700696 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Family Treatment Drug Court with Medications for Opioid Use Disorders (MOUD)
Description: Incentivized to participate in Family Treatment Drug Court with option for Medications for Opioid Use Disorders (MOUD)